MedPath

Clinical validation study to evaluate the efficacy and safety of Unani pharmacopoeial formulation-Majun Zanjabeel in Kasrat-e-Tams(Heavy Menstrual Bleeding)

Completed
Conditions
Abnormal uterine and vaginal bleeding, unspecified,
Registration Number
CTRI/2021/05/033350
Lead Sponsor
Central Council for Research in Unani Medicine
Brief Summary

This is an Open label single arm clinical study which will be done in Regional Institute for Unani Medicine Srinagar in which the efficacy and safety of Unani Pharmacopeial formulation Majun Zanjabeel will be assessed in patients of Kasrat e tams  (heavy menstrual bleeding)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
110
Inclusion Criteria

Non Gravid females of reproductive age patients with menorrhagia as indicated by i) Excessive menstrual loss greater than 80 ml per cycle as calculated by menstrual pictogram ii) Menstrual cycle greater than 6 days.

Exclusion Criteria
  • Heavy Menstrual Bleeding with structural or histological abnormality with symptoms such as Intermenstrual or post coital bleeding pelvic pain and or pressure symptoms 2.
  • Patients presenting with Heavy Menstrual Bleeding since menoarche •Patients with a personal or family history suggesting a coagulation disorder •Patients using Intrauterine Contraceptive Devices •Patients with illness requiring long term treatment e.g Hypertension TB etc •Patients with Post-menopausal bleeding •Patients with HMB taking Hormone Replacement Therapy •Conditions where HBM is not the main presenting menstrual symptom eg endometriosis •Pregnant and lactating females.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Decrease in blood loss during the menstural cycle .patients will be assessed at 4 weeks followed by 8 weeks and 12 weeks
Secondary Outcome Measures
NameTimeMethod
safety of drug in terms of vital and laboratory parametersfor vitals the patients will be assessed at baseline followed by 4 weeks 8 week and 12 week whereas, for laboratory parameters patients will be assessed at baseline and at 12 week of the study

Trial Locations

Locations (1)

Regional Research Institute of Unani Medicine

🇮🇳

JAMMU, & KASHMIR, India

Regional Research Institute of Unani Medicine
🇮🇳JAMMU, & KASHMIR, India
Dr Arjumand Shah
Principal investigator
7006180746
dr.arjumandshah111@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.